{"id":"uridine-triphosphate","rwe":[],"tags":[{"label":"uridine triphosphate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"P2Y purinoceptor 2","category":"target"},{"label":"P2RY2","category":"gene"},{"label":"P2RY4","category":"gene"},{"label":"P2RX3","category":"gene"},{"label":"Active","category":"status"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"uteplex","offLabel":[],"synonyms":["uridine triphosphate","UTP","uteplex"],"timeline":[],"aiSummary":"Uteplex, also known as Uridine Triphosphate, is a small molecule drug that targets the P2Y purinoceptor 2. It is classified as a uridine triphosphate and its mechanism of action is not well-documented. There is limited information available on Uteplex, including its commercial status, approved indications, and safety considerations. Further research is needed to fully understand its properties and potential uses. As a result, it is difficult to provide a comprehensive summary of Uteplex at this time.","approvals":[],"brandName":"Uteplex","ecosystem":[],"mechanism":{"target":"P2Y purinoceptor 11, P2Y purinoceptor 4, P2Y purinoceptor 6","targets":[{"gene":"P2RY2","source":"DrugCentral","target":"P2Y purinoceptor 2","protein":"P2Y purinoceptor 2"},{"gene":"P2RY4","source":"DrugCentral","target":"P2Y purinoceptor 4","protein":"P2Y purinoceptor 4"},{"gene":"P2RX3","source":"DrugCentral","target":"P2X purinoceptor 3","protein":"P2X purinoceptor 3"},{"gene":"P2RY11","source":"DrugCentral","target":"P2Y purinoceptor 11","protein":"P2Y purinoceptor 11"},{"gene":"P2RY6","source":"DrugCentral","target":"P2Y purinoceptor 6","protein":"P2Y purinoceptor 6"}],"modality":"Small Molecule","drugClass":"uridine triphosphate","explanation":"Imagine your cells have special locks on them, and Uteplex is a key that fits into one of those locks. When it binds, it can trigger a response that helps the cell do its job. This can be important for things like cell growth and communication.","oneSentence":"Uteplex works by binding to the P2Y purinoceptor 2, a receptor involved in various cellular processes.","technicalDetail":"Uteplex binds to the P2Y2 receptor, a subtype of purinergic receptor, which is activated by extracellular nucleotides and plays a role in various physiological processes, including cell proliferation and differentiation."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3639","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=URIDINE%20TRIPHOSPHATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=URIDINE TRIPHOSPHATE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T16:11:50.781156","biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"uridine triphosphate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04879368","phase":"PHASE3","title":"RegoNivo vs Standard of Care Chemotherapy in AGOC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-06-01","conditions":["Gastro-Oesophageal Cancer"],"enrollment":450,"completionDate":"2026-06-01"},{"nctId":"NCT06110598","phase":"PHASE2","title":"CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)","status":"WITHDRAWN","sponsor":"Case Comprehensive Cancer Center","startDate":"2024-12-01","conditions":["Pancreas Cancer","Pancreas Adenocarcinoma"],"enrollment":0,"completionDate":"2027-12-31"},{"nctId":"NCT05536596","phase":"PHASE2,PHASE3","title":"Pharmacological Treatment on the Recovery of Neurosensory Disturbance After Bilateral Sagittal Split Osteotomy","status":"UNKNOWN","sponsor":"Universitat Internacional de Catalunya","startDate":"2022-09-30","conditions":["Retrognathism","Prognathism","Orthognathic Surgery","Neurosensory Disorder"],"enrollment":220,"completionDate":"2024-12-31"},{"nctId":"NCT03738943","phase":"EARLY_PHASE1","title":"Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults","status":"COMPLETED","sponsor":"Colorado State University","startDate":"2019-02-07","conditions":["Receptor Blockade"],"enrollment":9,"completionDate":"2021-06-01"},{"nctId":"NCT00978250","phase":"PHASE2","title":"A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-08-20","conditions":["Head and Neck Neoplasms","Lung Neoplasms","Urinary Bladder Neoplasms","Breast Neoplasms"],"enrollment":95,"completionDate":"2019-04-11"},{"nctId":"NCT00210080","phase":"PHASE3","title":"A Study to Diagnose Lung Cancer by Sputum Cytology (01-312)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-04","conditions":["Lung Cancer"],"enrollment":700,"completionDate":"2003-12"},{"nctId":"NCT00004705","phase":"NA","title":"Study of Uridine Triphosphate (UTP) as an Aerosol Spray for Cystic Fibrosis","status":"COMPLETED","sponsor":"FDA Office of Orphan Products Development","startDate":"1996-09","conditions":["Cystic Fibrosis"],"enrollment":0,"completionDate":"1999-01"},{"nctId":"NCT00033527","phase":"NA","title":"INS316 Compared With Saline for Sputum Collection in Diagnosing Lung Cancer","status":"UNKNOWN","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"","conditions":["Lung Cancer"],"enrollment":0,"completionDate":""},{"nctId":"NCT00008255","phase":"PHASE2","title":"INS316 in Diagnosing Lung Cancer in Patients With Untreated Lung Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2000-08","conditions":["Lung Cancer"],"enrollment":0,"completionDate":"2004-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"05161190OB","CHEBI":"CHEBI:15713","UMLSCUI":"C0042010","ChEMBL_ID":"CHEMBL336296","DRUGBANK_ID":"DB04005","PDB_CHEM_ID":"UTP","PUBCHEM_CID":"6133","IUPHAR_LIGAND_ID":"1734","MESH_DESCRIPTOR_UI":"D014544"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}